Literature DB >> 9794233

Mutation analysis of the PTEN/MMAC1 gene in lung cancer.

E Forgacs1, E J Biesterveld, Y Sekido, K Fong, S Muneer, I I Wistuba, S Milchgrub, R Brezinschek, A Virmani, A F Gazdar, J D Minna.   

Abstract

We studied PTEN/MMAC1, a newly discovered candidate tumor suppressor gene at 10q23.3, for mutations in lung cancer. One hundred and thirty-six lung cancer cell line DNAs (66 small cell lung cancers, SCLC, 61 non-small cell lung cancers, NSCLC, four mesotheliomas, five extrapulmonary small cell cancers) were analysed for PTEN/MMAC1 homozygous deletions and five (8%) SCLC lines showed homozygous deletions interrupting the PTEN/MMAC1 gene. Using single stranded conformation polymorphism (SSCP) analysis, we screened the PTEN/MMAC1 open reading frame of 53 lung cancer cell line cDNAs for point mutations and found that 3/35 SCLCs and 3/18 NSCLCs contained homozygous amino acid sequence altering mutations. Northern blot analysis revealed that expression of the PTEN/MMAC1 gene was considerably lower in all the tumor cell lines with point mutations while no expression was detected for cell lines with PTEN/MMAC1 homozygous deletions. Mutation analysis of 22 uncultured, microdissected, primary SCLC tumors and metastases showed two silent mutations, and two apparent homozygous deletions. We also discovered a processed pseudogene (PTEN2) which has 98.5% nt identity to PTEN/MMAC1, that needs to be accounted for in cDNA mutation analysis. Our findings suggest that genetic abnormalities of the PTEN/MMAC1 gene are only involved in a relatively small subset of lung cancers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9794233     DOI: 10.1038/sj.onc.1202070

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  57 in total

Review 1.  Molecular genetic abnormalities in the pathogenesis of human lung cancer.

Authors:  E Forgacs; S Zöchbauer-Müller; E Oláh; J D Minna
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

2.  Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study.

Authors:  Thanyanan Reungwetwattana; Julian R Molina; Sumithra J Mandrekar; Katie Allen-Ziegler; Kendrith M Rowland; Nicholas F Reuter; Ronnie F Luyun; Grace K Dy; Randolph S Marks; Steven E Schild; James R Jett; Alex A Adjei
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

3.  PTEN polymorphisms contribute to clinical outcomes of advanced lung adenocarcinoma patients treated with platinum-based chemotherapy.

Authors:  Yang Yang; Wen Xu; Di Liu; Xi Ding; Bo Su; Yifeng Sun; Wen Gao
Journal:  Tumour Biol       Date:  2015-12-22

Review 4.  Signaling mechanisms in neuroendocrine tumors as targets for therapy.

Authors:  Barbara Zarebczan; Herbert Chen
Journal:  Endocrinol Metab Clin North Am       Date:  2010-12       Impact factor: 4.741

Review 5.  Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Authors:  Burhan Hassan; Argun Akcakanat; Ashley M Holder; Funda Meric-Bernstam
Journal:  Surg Oncol Clin N Am       Date:  2013-08-06       Impact factor: 3.495

6.  Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha.

Authors:  Harish Srinivas; Dianren Xia; Nicole L Moore; Ivan P Uray; Heetae Kim; Long Ma; Nancy L Weigel; Powel H Brown; Jonathan M Kurie
Journal:  Biochem J       Date:  2006-05-01       Impact factor: 3.857

7.  PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.

Authors:  Xia Pu; Michelle A T Hildebrandt; Charles Lu; Jie Lin; David J Stewart; Yuanqing Ye; Jian Gu; Margaret R Spitz; Xifeng Wu
Journal:  Lung Cancer       Date:  2010-05-05       Impact factor: 5.705

Review 8.  Overview upon miR-21 in lung cancer: focus on NSCLC.

Authors:  Cecilia Bica-Pop; Roxana Cojocneanu-Petric; Lorand Magdo; Lajos Raduly; Diana Gulei; Ioana Berindan-Neagoe
Journal:  Cell Mol Life Sci       Date:  2018-07-20       Impact factor: 9.261

9.  Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer.

Authors:  Kentaro Iwanaga; Yanan Yang; Maria Gabriela Raso; Lijiang Ma; Amy E Hanna; Nishan Thilaganathan; Seyed Moghaddam; Christopher M Evans; Huaiguang Li; Wei-Wen Cai; Mitsuo Sato; John D Minna; Hong Wu; Chad J Creighton; Francesco J Demayo; Ignacio I Wistuba; Jonathan M Kurie
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701

Review 10.  Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors.

Authors:  Yi Shao; Dian-Sheng Zhong
Journal:  Int J Clin Oncol       Date:  2017-11-07       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.